gefitinib has been researched along with cediranib in 12 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (cediranib) | Trials (cediranib) | Recent Studies (post-2010) (cediranib) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 279 | 102 | 204 |
Protein | Taxonomy | gefitinib (IC50) | cediranib (IC50) |
---|---|---|---|
Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.005 | |
Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.026 | |
Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.036 | |
Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.005 | |
Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.003 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0016 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 8 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Capuzzi, SJ; Fisher, EG; García-Sastre, A; He, S; Li, H; Martínez-Romero, C; Muratov, EN; Qiu, X; Shinn, P; Sun, W; Tawa, G; Tropsha, A; Xu, M; Zheng, W; Zhu, W | 1 |
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
Giaccone, G; Hoekman, K; Kater, M; Manoliu, RA; Meijerink, MR; van Cruijsen, H; van Schaik, C; van Waesberghe, JH | 1 |
Arao, T; Fukuoka, K; Kimura, H; Komatsu, T; Nishio, K; Saijo, N; Sasaki, H; Takeda, M; Tamura, T; Yamada, Y; Yanagihara, K; Yokote, H | 1 |
Bozec, A; Formento, P; Hofman, P; Lassalle, S; Lippens, C; Milano, G | 1 |
de Gruijl, TD; Giaccone, G; Hoekman, K; Kuenen, BC; Scheper, RJ; Stam, AG; van Cruijsen, H; van den Eertwegh, AJ | 1 |
Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO | 1 |
Brown, N; Clifton-Hadley, L; Dungey, F; Hopkins, K; Jeffries, S; Khan, I; Krell, D; McBain, C; Mulholland, P; Nash, S; Phillips, M; Sanghera, P; Saran, F; Smith, P; Wanek, K | 1 |
1 review(s) available for gefitinib and cediranib
Article | Year |
---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
4 trial(s) available for gefitinib and cediranib
Article | Year |
---|---|
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.
Topics: Administration, Oral; Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Contrast Media; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gefitinib; Humans; Image Processing, Computer-Assisted; Injections, Intravenous; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pelvic Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Tomography, Spiral Computed | 2007 |
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dendritic Cells; Female; Flow Cytometry; Gefitinib; Humans; Male; Middle Aged; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Therapy, Combination; ErbB Receptors; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Netherlands; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Placebos; Quality of Life; Quinazolines; Recurrence; Safety; Vascular Endothelial Growth Factor A | 2016 |
7 other study(ies) available for gefitinib and cediranib
Article | Year |
---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Drug Discovery; Drug Evaluation, Preclinical; Ebolavirus; HeLa Cells; Humans; Molecular Structure; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Virus Internalization | 2018 |
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dimerization; Gefitinib; Humans; Mice; Mice, Inbred Strains; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Stomach Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2007 |
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2007 |